GlobeNewswire: Advanced Bifurcation Systems Contains the last 10 of 7 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T07:22:23ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/09/21/1574495/0/en/Advanced-Bifurcation-Systems-Files-Pre-Submission-With-FDA-to-Define-Clinical-Pathway-Outlines-Regulatory-and-Clinical-Strategy-for-Europe-to-Obtain-CE-Mark.html?f=22&fvtc=4&fvtv=38534Advanced Bifurcation Systems Files Pre-Submission With FDA to Define Clinical Pathway; Outlines Regulatory and Clinical Strategy for Europe to Obtain CE Mark2018-09-21T19:07:28Z<![CDATA[LOS ANGELES, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that the Company has submitted a proposal to the U.S. Federal Drug Administration (“FDA”) for a clinical study leading to an IDE for its bifurcation technology. Concurrently, the Company is defining a regulatory and clinical strategy for Europe to receive a CE mark.]]>https://www.globenewswire.com/news-release/2018/09/21/1574494/0/en/Advanced-Bifurcation-Systems-Granted-Four-Additional-Patents.html?f=22&fvtc=4&fvtv=38534Advanced Bifurcation Systems Granted Four Additional Patents2018-09-21T19:02:57Z<![CDATA[LOS ANGELES, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that the Company has been granted four additional patents, three in the U.S. and one in Europe.]]>https://www.globenewswire.com/news-release/2018/06/27/1530244/0/en/Advanced-Bifurcation-Selected-to-Join-MaRS-Venture-Services.html?f=22&fvtc=4&fvtv=38534Advanced Bifurcation Selected to Join MaRS Venture Services2018-06-27T12:00:00Z<![CDATA[Company Secures Trademark for ABS and ABS Mother-Daughter Company Secures Trademark for ABS and ABS Mother-Daughter]]>https://www.globenewswire.com/news-release/2018/01/25/1304891/0/en/Advanced-Bifurcation-Systems-Appoints-Industry-Veteran-Thomas-O-Neill-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=38534Advanced Bifurcation Systems Appoints Industry Veteran Thomas O’Neill to Board of Directors2018-01-25T13:00:00Z<![CDATA[Founding Principal of Sandler O'Neill to Bring Deep Financial Services Expertise and World-Class Relationships to ABS Founding Principal of Sandler O'Neill to Bring Deep Financial Services Expertise and World-Class Relationships to ABS]]>https://www.globenewswire.com/news-release/2017/10/30/1159888/0/en/Advanced-Bifurcation-Systems-Announces-Appointment-of-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=38534Advanced Bifurcation Systems Announces Appointment of Chief Financial Officer2017-10-30T12:01:00Z<![CDATA[LOS ANGELES, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced the appointment of Ken Richards as Chief Financial Officer.]]>https://www.globenewswire.com/news-release/2017/10/03/1140049/0/en/Advanced-Bifurcation-Systems-Announces-Plan-for-Human-Clinical-Trials-in-New-Brunswick-Canada.html?f=22&fvtc=4&fvtv=38534Advanced Bifurcation Systems Announces Plan for Human Clinical Trials in New Brunswick, Canada2017-10-03T11:55:00Z<![CDATA[LOS ANGELES, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that the Company is planning to undertake human clinical trials in New Brunswick, Canada. The planning for these clinical trials has been initiated with the participation of Dalhousie University’s Medical School (DMNB), Horizon Health Network (HHN) where the New Brunswick Heart Center is located, and the New Brunswick Health Research Foundation (NBHRF). The introduction to these institutions was spearheaded by Opportunities NB.]]>https://www.globenewswire.com/news-release/2017/09/18/1124040/0/en/Advanced-Bifurcation-Systems-to-Sponsor-XIII-European-Bifurcation-Club-Meeting.html?f=22&fvtc=4&fvtv=38534Advanced Bifurcation Systems to Sponsor XIII European Bifurcation Club Meeting2017-09-18T11:55:00Z<![CDATA[LOS ANGELES, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that the Company will be a sponsor of the XIII European Bifurcation Club (www.bifurc.net) meeting at the Casa Das Artes in Porto, Portugal on Friday, October 13th and Saturday, October 14th, 2017. Dr. Mehran Khorsandi, the Company’s co-founder, chairman and chief medical officer will make a presentation entitled "Bifurcations Made Easy" at the conference.]]>